Monthly News Roundup - October 2023
FDA Clears Loqtorzi as First Treatment for Nasopharyngeal Carcinoma (NPC)
In October, the U.S. Food and Drug Administration (FDA) approved Coherus BioSciences’ Loqtorzi (toripalimab-tpzi) to treat adult patients with metastatic or recurrent... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - October 31, 2023 Category: Pharmaceuticals Source Type: news
FDA Approves Toripalimab for Nasopharyngeal Carcinoma FDA Approves Toripalimab for Nasopharyngeal Carcinoma
This marks the first approval for toripalimab.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - October 31, 2023 Category: Cancer & Oncology Tags: Hematology-Oncology News Alert Source Type: news
FDA OKs First Drug for Nasopharyngeal Carcinoma
(MedPage Today) -- The FDA approved a new PD-1 inhibitor, toripalimab (Loqtorzi), for treating adults with metastatic or recurrent nasopharyngeal carcinoma (NPC), representing the first drug specifically approved for this patient population.
Toripalimab... (Source: MedPage Today Public Health)
Source: MedPage Today Public Health - October 30, 2023 Category: American Health Source Type: news
FDA Approves Loqtorzi (toripalimab-tpzi) in All Lines of Treatment for Recurrent or Metastatic Nasopharyngeal Carcinoma (NPC)
REDWOOD CITY, Calif. and SHANGHAI, China, Oct. 27, 2023 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus”, NASDAQ: CHRS), and Shanghai Junshi Biosciences Co., Ltd. (Junshi Biosciences, HKEX: 1877; SSE: 688180) today announced that... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - October 27, 2023 Category: Drugs & Pharmacology Source Type: news
Threshold of 6 mm on Retropharyngeal Lymph Node Predicts PFS in Nasopharyngeal Carcinoma
MONDAY, Oct. 2, 2023 -- For patients with nasopharyngeal carcinoma (NPC), a minimal axial diameter (MAD) threshold of 6 mm for retropharyngeal lymph node (RLN) predicts survival, according to a study published online Sept. 27 in the American Journal... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - October 2, 2023 Category: Pharmaceuticals Source Type: news
Novel Biomarker Boosts Diagnostic Accuracy of Nasopharyngeal Cancer Screening
(MedPage Today) -- A novel biomarker derived from Epstein-Barr virus (EBV) significantly improved the diagnostic accuracy for nasopharyngeal carcinoma, a large screening study from China showed.
Screening with P85-Ab, an anti-BNLF2b total antibody... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - August 30, 2023 Category: Hematology Source Type: news
Alternative Drug Combo Option in Nasopharyngeal Carcinoma? Alternative Drug Combo Option in Nasopharyngeal Carcinoma?
The findings suggest better outcomes and tolerable safety with adjuvant cisplatin-gemcitabine compared with the current standard ― cisplatin-fluorouracil.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - June 23, 2023 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
Coherus Announces Positive Final Overall Survival Results of JUPITER-02 Phase 3 Trial Evaluating Toripalimab in Nasopharyngeal Carcinoma
REDWOOD CITY, Calif., June 05, 2023 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS) announced the final overall survival (OS) results of the JUPITER-02 study presented today at the American... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - June 5, 2023 Category: General Medicine Source Type: news
Improved OS With Hyperfractionated RT in Recurrent Nasopharyngeal Carcinoma
(MedPage Today) -- Compared with standard fractionation, hyperfractionated intensity-modulated radiotherapy (IMRT) could significantly increase overall survival (OS), as well as reduce the rate of severe late complications in patients with locally... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - March 21, 2023 Category: Hematology Source Type: news
Data Hint COVID-19 Vax May Improve Immunotherapy Efficacy in Some Data Hint COVID-19 Vax May Improve Immunotherapy Efficacy in Some
Patients with nasopharyngeal cancer who received the Chinese Sinovac COVID-19 vaccine did better on immune checkpoint inhibitor therapy compared with unvaccinated patients, early data suggest.Medscape Medical News (Source: Medscape Infectious Diseases Headlines)
Source: Medscape Infectious Diseases Headlines - November 21, 2022 Category: Infectious Diseases Tags: Hematology-Oncology News Source Type: news
COVID vaccination improves effectiveness of cancer treatment
Patients with nasopharyngeal cancer are often treated with drugs that activate their immune system against the tumor. Until now, it was feared that vaccination against Covid-19 could reduce the success of cancer treatment or cause severe side effects. A recent study by the Universities of Bonn and Shanxi in the People's Republic of China now gives the all-clear in this regard. (Source: World Pharma News)
Source: World Pharma News - November 9, 2022 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news
Radiation Alone May Suffice for Some Nasopharyngeal Cancer
(MedPage Today) -- CHICAGO – In selected patients with nasopharyngeal carcinoma, radiation alone may do as much against the disease as the combination of radiation and chemotherapy but with fewer adverse effects, researchers suggested here... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - June 6, 2022 Category: Hematology Source Type: news
Is Nasopharyngeal Cancer Head and Neck Cancer?
Title: Is Nasopharyngeal Cancer Head and Neck Cancer?Category: Diseases and ConditionsCreated: 5/12/2022 12:00:00 AMLast Editorial Review: 5/12/2022 12:00:00 AM (Source: MedicineNet Cancer General)
Source: MedicineNet Cancer General - May 12, 2022 Category: Cancer & Oncology Source Type: news
Adding Tislelizumab to Chemo Slows Advanced Nasopharyngeal Cancer
FRIDAY, April 22, 2022 -- The addition of tislelizumab to chemotherapy improves progression-free survival (PFS) in recurrent/metastatic nasopharyngeal cancer (RM NPC), according to a study presented April 18 as part of the American Society for... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - April 22, 2022 Category: Pharmaceuticals Source Type: news
PD-1 Inhibition Shows 'Clear' Benefit in Nasopharyngeal Carcinoma
(MedPage Today) -- Adding the PD-1 inhibitor tislelizumab to chemotherapy led to a progression-free survival (PFS) improvement for patients with recurrent or metastatic nasopharyngeal carcinoma (NPC), according to updated results from a phase III... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - April 20, 2022 Category: Hematology Source Type: news
